Cambridge, MA, July 9, 2020 — TriNetX, the global health research network that optimizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced that the Journal of Psychopharmacologyhas published an article on a study of comparative rates of delirium of various types of antihypertensive drugs (AHTs) that used real-world data from TriNetX. The article, titled Rates of delirium associated with calcium channel blockers compared to diuretics, renin-angiotensin system agents and beta-blockers: An electronic health records network study, was written by Paul Harrison and Lucy Colbourne of the University of Oxford, Department of Psychiatry and Oxford Health NHS Foundation Trust, and Sierra Luciano, TriNetX. The study found that calcium channel blockers (CCBs) are associated with higher rates of delirium than renin-angiotensin system (RAS agents), but lower rates compared to beta-blockers.
The study used the TriNetX analytics network, Dataworks, which allowed access to de-identified data from over 61 million patients in 46 healthcare organizations (HCOs) in the U.S. The available data, collected since 2007, included extensive information on demographics, diagnoses using ICD-10 codes, medications, procedures, and lab values.
“To my knowledge, this is one of the first studies of delirium using real-world data and certainly the largest,” said Harrison. “The unusually large sample size and richness of data available allowed us to examine and control for many possible confounders, including confounding by indications such as factors which influence the choice of AHT class and for other risk factors for delirium like sepsis, surgery, and digitalis.”
AHTs, especially CCBs, have been associated with differential rates of a number of neuropsychiatric outcomes. Delirium is commonly attributed to medication, including AHTs, but delirium incidence has not been compared directly between AHT classes. Extensive propensity scoring matching was used to create cohorts matched for a range of demographic factors and delirium risk factors. The article is currently available for download on the Journal of Psychopharmacology website.
“The findings show the value of large pharmacoepidemiologic datasets linked to electronic medical records,” said Sierra Luciano, Research Manager, Clinical Sciences at TriNetX. “In addition, the richness of the data available on the TriNetX network allowed the study authors to reveal, and then to minimize, the extent of confounding which can compromise studies of this kind.”
TriNetX has partnered with healthcare organizations spanning 27 countries to create a linked and continually updated global health research network representing over 400 million patients. TriNetX has been used to analyze over 26,000 protocols, presented over 7,000 clinical trial opportunities to its HCO members and been used for real-world evidence research presented at scientific conferences and in peer-reviewed publications.
####
About TriNetX
TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.
Media Contact
TriNetX
Jennifer Haas
(857) 285-6052
Jennifer.haas@trinetx.com
